Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
151.28
-16.25 (-9.70%)
At close: May 6, 2026, 4:00 PM EDT
153.00
+1.72 (1.14%)
Pre-market: May 7, 2026, 4:58 AM EDT
Insulet Employees
Insulet had 5,400 employees as of December 31, 2025. The number of employees increased by 1,500 or 38.46% compared to the previous year.
Employees
5,400
Change (1Y)
1,500
Growth (1Y)
38.46%
Revenue / Employee
$537,185
Profits / Employee
$56,074
Market Cap
10.48B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,400 | 1,500 | 38.46% |
| Dec 31, 2024 | 3,900 | 900 | 30.00% |
| Dec 31, 2023 | 3,000 | 400 | 15.38% |
| Dec 31, 2022 | 2,600 | 300 | 13.04% |
| Dec 31, 2021 | 2,300 | 400 | 21.05% |
| Dec 31, 2020 | 1,900 | 550 | 40.74% |
| Dec 31, 2019 | 1,350 | 181 | 15.48% |
| Dec 31, 2018 | 1,169 | 312 | 36.41% |
| Dec 31, 2017 | 857 | 217 | 33.91% |
| Dec 31, 2016 | 640 | -7 | -1.08% |
| Dec 31, 2015 | 647 | 128 | 24.66% |
| Dec 31, 2014 | 519 | 41 | 8.58% |
| Dec 31, 2013 | 478 | -60 | -11.15% |
| Dec 31, 2012 | 538 | -38 | -6.60% |
| Dec 31, 2011 | 576 | 266 | 85.81% |
| Dec 31, 2010 | 310 | 34 | 12.32% |
| Dec 31, 2009 | 276 | -18 | -6.12% |
| Dec 31, 2008 | 294 | 47 | 19.03% |
| Dec 31, 2007 | 247 | -47 | -15.99% |
| Dec 31, 2006 | 294 | 47 | 19.03% |
| Dec 31, 2005 | 247 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| STERIS | 17,787 |
| Zimmer Biomet Holdings | 17,000 |
| Smith & Nephew | 16,988 |
| DexCom | 11,100 |
| Bruker | 11,085 |
| Bio-Rad Laboratories | 7,450 |
| Bio-Rad Laboratories | 7,450 |
| Globus Medical | 6,000 |
PODD News
- 21 hours ago - Insulet Earnings Call Transcript: Q1 2026 - Transcripts
- 21 hours ago - Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand - Reuters
- 22 hours ago - Insulet Reports First Quarter 2026 Results - Business Wire
- 1 day ago - Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities - Business Wire
- 2 days ago - Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes - Business Wire
- 7 days ago - FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns - Benzinga
- 8 days ago - Insulet to Participate in BofA Securities 2026 Health Care Conference - Business Wire
- 5 weeks ago - Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 - Business Wire